Belite Bio's lead drug, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data expected by late 2024 or early 2025. Tinlarebant works by reducing ...
Korro Bio, Inc. (KRRO) is a biotech that is working on advancing its RNA editing platform OPERA to treat certain types of disorders. The first RNA edited oligonucleotide drug of its kind from this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback